Application of a preparation inhibiting piRNA-005854 in the preparation of a drug for treating cardiac ischemia-reperfusion injury
By inhibiting the preparation of piRNA-005854, the problem of serious injury after reperfusion in patients with ischemic heart disease is solved, especially the protection of aging myocardium, effectively alleviating ischemic reperfusion injury and providing a new therapeutic target.
Patent Information
- Application Number
- CN202310523042.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-10
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2043-05-10
AI Technical Summary
Patients with ischemic heart disease are prone to injury after reperfusion. The existing technology lacks effective treatment methods, especially the protective mechanism for aging myocardium, resulting in serious ischemic and reperfusion injury.
A preparation that inhibits piRNA-005854 was developed to prepare a therapeutic drug for cardiac ischemia-reperfusion injury, which alleviates hypoxia-reoxygenation-induced damage by inhibiting apoptosis, autophagy and ULK1 phosphorylation of aging cardiomyocytes.
It effectively reduces the autophagy and apoptosis of aging cardiomyocytes, reduces ischemia and reperfusion injury, provides new therapeutic targets, and provides new ideas for drug research on ischemic heart disease.
Smart Images

Figure CN116763924B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medical technology, and in particular relates to the use of a preparation for inhibiting piRNA-005854 in the preparation of a drug for treating cardiac ischemia-reperfusion injury. Background Art
[0002] Ischemic heart disease (IHD) is the main cause of death among cardiovascular diseases. When coronary reperfusion is performed for ischemic heart disease in clinical practice, ischemic myocardial tissue is susceptible to re-injury, namely myocardial ischemia / reperfusion injury (MIRI), which may manifest as reperfusion arrhythmias, myocardial stunning, microvascular occlusion, intramyocardial hemorrhage, and even sudden death. At present, research on reducing reperfusion injury mainly focuses on pretreatment before ischemia and post-ischemia treatment. Since the time point of ischemia in clinical patients is difficult to predict, pretreatment needs to be given before ischemia. Therefore, post-ischemia treatment is more practical and clinically valuable in clinical practice. Post-ischemia treatment is repeated and short-term reperfusion / ischemia treatment after ischemia in tissues and organs before reperfusion in clinical practice, which is conducive to mobilizing the endogenous protective mechanism of the body to reduce tissue reperfusion injury. A large number of clinical cases have found that 50% of myocardial infarction patients and 80% of patients who died from myocardial infarction were over 65 years old, and the mortality rate increased year by year with age. So far, there is still a lack of effective treatment. At the same time, a large number of studies have confirmed that aging does increase the susceptibility of myocardial ischemia and the degree of reperfusion injury. Therefore, exploring the mechanism by which ischemic postconditioning of aged myocardium exerts its protective effect is one of the keys to reducing ischemia-reperfusion injury.
[0003] Autophagy is a cell degradation and recycling process that is highly conserved in all eukaryotic cells. Studies have shown that autophagy plays an important regulatory role in cardiomyocyte function. When acute myocardial ischemia occurs, cells are stimulated by exogenous stimuli to activate autophagy. If autophagy exceeds a certain level, some important proteins or organelles will be damaged, affecting the normal function of cells and causing autophagic death. Recent studies have also shown that one of the important causes of organ microcirculatory dysfunction caused by ischemia-reperfusion injury is the abnormal apoptosis of cardiomyocytes induced by the loss of important proteins and organelles in the cytoplasm caused by autophagy. Phosphorylated ULK1 has always been considered a key regulator of autophagy. Phosphorylation activates ULK1 and promotes the formation of autophagosomes. Studies have found that autophagy regulated by ULK1 can affect cardiovascular diseases. For example, in high-glucose-induced myocardial injury, ULK1 inactivation can inhibit cell autophagy and protect cardiomyocytes from high-glucose toxicity.
[0004] piRNA plays an important role in maintaining the stability of the eukaryotic cell genome. Recent studies have shown that piRNA is highly expressed in the heart. The expression profile of piRNA in cardiac pathological models is significantly changed compared with normal hearts. A large number of piRNAs are upregulated or downregulated. After artificial intervention in piRNA expression, the phenotype of heart disease is significantly alleviated. Therefore, piRNA has great research value for heart-related diseases. Teng Zengguang et al. also found that piRNA-DQ765261 can downregulate the expression of Bcl-xL protein by regulating and activating the AMPK / ULK signaling pathway, and jointly promote the expression of Beclin1, thereby inducing autophagy. In this patent, we first sequenced the aged cardiomyocytes in the Normoxia group, H / R group, and HPostC group. The sequencing results showed that piRNA-005854 was a differential gene in the three groups of cardiomyocytes.
[0005] In summary, we explored the effects of H / R and HPostC on the expression of piRNA-005854 and autophagy in aged myocardium, which may help protect the myocardium from I / R injury and hopefully identify new targets for the treatment of ischemic heart disease. Summary of the invention
[0006] In view of the above technical problems, the present invention provides the use of a preparation for inhibiting piRNA-005854 in the preparation of a drug for treating cardiac ischemia-reperfusion injury. The piRNA-005854 sequence is shown in SEQ ID NO.1.
[0007] Furthermore, the drug inhibits apoptosis of senescent cardiomyocytes.
[0008] Furthermore, the drug inhibits myocardial cell apoptosis caused by autophagy of aged myocardial cells.
[0009] Furthermore, the drug inhibits autophagy of aged cardiomyocytes caused by increased LC3Ⅱ / Ⅰ and decreased p62.
[0010] Furthermore, the drug inhibits the increase in LC3Ⅱ / Ⅰ and the decrease in p62 caused by the increase in ULK1 phosphorylation.
[0011] Furthermore, the drug inhibits the increase in ULK1 phosphorylation induced by hypoxia-reoxygenation or hypoxic post-conditioning.
[0012] In another aspect, the present invention provides a drug for treating cardiac ischemia-reperfusion injury, wherein the active ingredient of the drug comprises a preparation that inhibits piRNA-005854;
[0013] The sequence of the piRNA-005854 is shown in SEQ ID NO.1.
[0014] The present invention has the following beneficial effects:
[0015] Myocardial ischemia / reperfusion (I / R) injury is the main problem for myocardial infarction patients to obtain the best therapeutic effect from reperfusion therapy. In-depth research on myocardial I / R injury and seeking new protective measures have become important issues facing the medical community. In recent years, the role of piRNA in heart disease has attracted attention at home and abroad. It is mainly involved in the development of the heart, myocardial injury and repair, myocardial hypertrophy and myocardial infarction, etc., but its application in ischemia-reperfusion injury has not yet been involved. In the present invention, we found that piRNA-005854 is a differential gene in aging cardiomyocytes of the Normoxia group, H / R group, and HPostC group. Then we proved that piRNA-005854 was upregulated in aging cardiomyocytes under the action of H / R, and post-treatment reduced the expression of piRNA-005854 in aging cardiomyocytes; at the same time, the study concluded that the downregulation of piRNA-005854 in the HPostC group can effectively reduce H / R-induced autophagy in aging cardiomyocytes, thereby alleviating ischemia-reperfusion injury of aging myocardium. This can provide new ideas for alleviating myocardial ischemia-reperfusion injury in aging and new targets for drug research on diseases such as IHD. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] Figure 1 β-galactosidase staining was used to detect the senescence of cardiomyocytes (×10). Figure A is the normal control group; Figure B is the senescent group: the arrows indicate senescent cardiomyocytes.
[0017] Figure 2 Figure 1 shows the damage of senescent myocardial cells in each group. Figure A shows the LDH content (ng / mL) in the supernatant of senescent myocardial cells; Figure B shows the CK-MB content (pg / mL) in the supernatant of senescent myocardial cells. Compared with the Normoxia group, a P<0.01; compared with the H / R group, b P<0.01.
[0018] Figure 3 Figures A, B, and C are Western blots to detect the expression of LC3Ⅱ / Ⅰ, p62, and p-ULK1 / ULK1 in senescent cardiomyocytes, and Figures D, E, and F are quantitative graphs of Figures A, B, and C, respectively. Compared with the Normoxia group, a P<0.01; compared with the H / R group, b P<0.01.
[0019] Figure 4Figure 1 shows the expression of piRNA-005854 in aged cardiomyocytes. Figure 1 shows the expression of piRNA-005854 in aged cardiomyocytes detected by qRT-PCR. Compared with the Normoxia group, a P<0.01; compared with the H / R group, b P<0.01.
[0020] Figure 5 Figure A is the expression level of piRNA-005854 inhibitor detected by qRT-PCR in aged cardiomyocytes; Figure B is the expression level of piRNA-005854 mimics detected by qRT-PCR in aged cardiomyocytes. Compared with the inhibitor-NC group, a P<0.01; compared with the mimics-NC group, b P<0.01.
[0021] Figure 6 Figures A and B are Western blots to detect the expression of LC3Ⅱ / Ⅰ and p62 proteins in aged cardiomyocytes after interfering with piRNA-005854; Figures C and D are Western blots to detect the expression of LC3Ⅱ / Ⅰ and p62 proteins in aged cardiomyocytes after overexpressing piRNA-005854; Figures E, F, G, and H are quantitative graphs of Figures A, B, C, and D, respectively. Compared with the H / R group, a P<0.01, c P<0.05; compared with HPostC+inhibitor-NC group, b P<0.01, d P<0.05; compared with HPostC+mimics-NC group, e P<0.01.
[0022] Figure 7 Figure 1 shows the effect of piRNA-005854 on the phosphorylation level of ULK1 in aged cardiomyocytes. Figure A shows the expression of ULK1 and p-ULK1 proteins in aged cardiomyocytes after interfering with piRNA-005854 by Western blot; Figure B shows the expression of ULK1 and p-ULK1 proteins in aged cardiomyocytes after overexpressing piRNA-005854 by Western blot. Figures C and D are the quantitative graphs of Figures A and B, respectively. Compared with the H / R group, a P<0.01; compared with the HPostC+inhiitor-NC group, b P<0.01; compared with HPostC+mimics-NC group, cP<0.01. DETAILED DESCRIPTION
[0023] The present invention is described in detail below in conjunction with the accompanying drawings and specific examples, but should not be construed as limiting the present invention. Unless otherwise specified, the technical means used in the following examples are conventional means well known to those skilled in the art, and the materials, reagents, etc. used in the following examples, unless otherwise specified, can be obtained from commercial sources.
[0024] Example
[0025] 1 Materials and Methods
[0026] 1.1 Experimental reagents and instruments
[0027] Rat cardiomyocyte cell line (H9C2) was purchased from Wuhan Punosai Biotechnology Co., Ltd.; 4× SDS-PAGE separation gel and stacking gel buffer were purchased from Beijing Jinclone Biotechnology Co., Ltd.; fetal bovine serum and DMEM culture medium were purchased from Gibco, USA; D-Galactose, penicillin-streptomycin-amphotericin B mixed solution, trypsin-EDTA digestion solution, and β-galactosidase staining kit were purchased from Beijing Solebow Technology Co., Ltd.; total RNA preparation kit was purchased from Axygen, USA; PrimeScript TM RT reagent Kit and TB Premix Ex Taq TM II was purchased from Takara, Japan; LC3 and p62 rabbit monoclonal antibodies were purchased from Abcam, USA; ULK1 and p-ULK1 rabbit monoclonal antibodies were purchased from Cell Signaling Technology; HRP-labeled goat anti-rabbit secondary antibody was purchased from Beijing Zhongshan Jinqiao Biotechnology Co., Ltd.; rat creatine kinase isozyme MB (CKMB) ELISA kit was purchased from Wuhan Elaruite Biotechnology Co., Ltd.; rat lactate dehydrogenase (LDH) ELISA kit was purchased from Shanghai Abima Pharmaceutical Technology Co., Ltd.; piRNA-005854 primers were synthesized by Guangzhou Ruibo Biotechnology Co., Ltd.; piRNA-005854 inhibitor and piRNA-005854 mimics were purchased from Shanghai Jima Pharmaceutical Technology Co., Ltd. BS110S precision balance and micro-table centrifuge were purchased from Eppendorf, Germany; fluorescence quantitative PCR instrument was purchased from Jena Analytical Instruments AG.
[0028] The piRNA-005854 inhibitor sequence is as follows:
[0029] sense: 5'-UAGUGCGGACACCCGAUCGGCAUAGCGCAC-3', shown in SEQ ID NO.2;
[0030] The piRNA-005854 mimic sequence is as follows:
[0031] sense: 5'-GUGCGCUAUGCCGAUCGGGUGUCCGCACUA-3', as shown in SEQ ID NO.3;
[0032] Antisense: 5'-GUGCGGACACCCGAUCGGCAUAGCGCACUU-3', shown in SEQ ID NO.4.
[0033] 1.2 Methods
[0034] 1.2.1 Cell culture
[0035] Cardiomyocytes were cultured with DMEM culture medium (containing 10% fetal bovine serum) in an incubator at 37°C, 95% O2, 5% CO2, and passaged when the cell confluence reached about 80%.
[0036] 1.2.2 Establishment and grouping of cell models
[0037] First, cells were stimulated with 8 mg / mL D-galactose for 9 days to induce cell senescence. Then, β-galactosidase staining was used to confirm the senescence of cardiomyocytes. Cardiomyocytes were plated at 5×10 6 The number of senescent cardiomyocytes was inoculated into culture flasks, and then the senescent cardiomyocytes were randomly divided into the normal oxygen group (Normoxia group), the hypoxia / reoxygenation group (H / R group), and the post-treatment group (HPostC group). Normoxia group: senescent cardiomyocytes; H / R group: based on the normal senescent cardiomyocytes in the Normoxia group, first hypoxia for 3 hours and then reoxygenation for 2 hours. HPostC group: after 3 hours of hypoxia, 3 cycles of 5 minutes of hypoxia / 5 minutes of reoxygenation were given. After the 3 cycles, 2 hours of reoxygenation were given.
[0038] 1.2.3 Detection of cardiomyocyte senescence by β-galactosidase staining
[0039] The control group cells (normal cardiomyocytes) and the senescent group cells (cardiomyocytes stimulated with 8 mg / mL D-galactose for 9 days) were cultured at 3×10 5The number of cells was inoculated into a 6-well plate, with 3 replicates per group. After the cells adhered to the wall, the cell culture medium was removed, and the cells were washed once with 1×PBS. 1ml of β-galactosidase staining fixative was added and fixed at room temperature for 15min. The fixative was discarded and washed 3 times with 1×PBS, 3min each time. PBS was discarded, 1ml of staining working solution was added to each well (the staining working solution was prepared in proportion in advance), and then placed in a 37°C incubator and incubated overnight. Under optical microscopy, the cell cytoplasm was blue, which was a staining-positive cell, confirming that it was a senescent cell.
[0040] 1.2.4 Cell transfection and experimental grouping
[0041] Senescent cardiomyocytes with good growth status were selected for culture, and inhibitor-NC, mimics-NC, piRNA-005854inhibitor and piRNA-005854mimics were transfected into senescent cardiomyocytes using INVI DNA RNA Transfection Reagent. 5 The number of cells was inoculated into a 6-well plate, and transfection was performed when the cell confluence was about 80%. First, prepare solution A: add 3μL INVI DNA RNA Transfection Reagent to 125μL DMEM culture medium (without serum), and incubate at room temperature for 5min; then prepare solution B: add 3μL of the sequence to be transfected to 125μL DMEM culture medium (without serum); mix solution A and solution B in a ratio of 1:1, shake and mix, and incubate at room temperature for 20min. After aspirating the culture medium in the plate and gently rinsing with new culture medium, add 250μL of the A and B mixture to the cell culture plate, and add 1750μL of DMEM culture medium (containing 10% serum) to each well, mix gently, and continue to culture in the incubator. After culturing for 24h, collect the cells for subsequent experiments, and set up 3 replicates for each group.
[0042] Experimental groups: piRNA-005854inhibitor and piRNA-005854mimics were transfected into senescent cardiomyocytes and then treated with HPostC. The experimental groups were: H / R group, HPostC group, HPostC+inhibitor-NC group, HPostC+piRNA-005854inhibitor group, HPostC+mimics-NC group, and HPostC+piRNA-005854mimics group.
[0043] 1.2.5 ELISA to detect aging cardiomyocyte damage
[0044] First, take the culture supernatant of aged cardiomyocytes in each group; add 100 μL of supernatant or standard working solution to the corresponding plate wells and incubate in a 37℃ incubator for 90 minutes; after 90 minutes, remove the liquid in the plate, then add 100 μL of biotinylated antibody working solution, and incubate in a 37℃ incubator for 60 minutes; after the incubation, remove the working solution in the plate and wash the plate 3 times; then add 100 μL of HRP enzyme conjugate working solution to the plate and incubate in a 37℃ incubator for 30 minutes; after the incubation, remove the liquid in the plate and wash the plate 5 times; then add 90 μL of substrate solution to the plate and incubate in a 37℃ incubator for 15 minutes; after 15 minutes, add 50 μL of stop solution to each well; after the reaction is terminated, use an enzyme reader to measure the absorbance value of the sample at a wavelength of 450 nm. The fitting curve is obtained with the standard concentration as the horizontal axis and the OD value as the vertical axis, and the best fitting curve is determined by regression analysis. The OD values of the reference and samples were inserted into the standard curve to calculate the sample concentration.
[0045] 1.2.6 Detection of differential expression of piRNA by real-time fluorescence quantitative PCR
[0046] According to the Axygen-total RNA extraction instructions, RNA from myocardial cells of each group was extracted; the concentration of the extracted RNA was determined, reverse transcribed into cDNA, and then amplified (primers were designed and synthesized by Guangzhou Ruibo Biotechnology Co., Ltd.). The qRT-PCR conditions were: 95℃ pre-denaturation for 30s, 95℃ denaturation for 5s, Tm annealing for 34s, and amplification cycles for 45. After the reaction, according to 2 -ΔΔCt The results of the analysis.
[0047] 1.2.7 Western Blot Verification of Cell Autophagy Levels
[0048] Take cells in the logarithmic growth phase, and when the cell confluence reaches 80%, collect the cells in each group and extract the total protein. Use a micro-nucleic acid protein concentration meter to detect the protein concentration and quantify it; after calculating the concentration, add the corresponding amount of SDS-PAGE Loading Buffer, denatured at 95℃ for 10min; after SDS-PAGE gel electrophoresis, the target protein band was cut out and transferred to a PVDF membrane by wet transfer, blocked with 5% skim milk for 2h at room temperature, incubated with rabbit monoclonal LC3 antibody (1:1000), p62 antibody (1:1000), p-ULK1 antibody (1:1000) and ULK1 antibody (1:1000) on a shaker at 4℃ overnight; washed the membrane 3 times with PBST, each time for 10min; incubated with HRP-labeled goat anti-rabbit IgG (1:5000) on a shaker at 4℃ for 4h; after the incubation, washed the membrane 3 times with PBST, each time for 10min; dipped in chemiluminescent solution and placed in an exposure instrument for development; using β-actin as an internal reference, the grayscale values of LC3, p62, p-ULK1 and ULK1 were quantitatively analyzed using ImageLab software.
[0049] 1.2.8 Statistical methods
[0050] The experimental results were all quantitative data. The quantitative data that conformed to the normal distribution were expressed as mean ± standard deviation (x ± s). Graphpad Prism statistical software was used to perform statistical analysis on the experimental data. The Student's t test was used to compare the results between the means of two samples, and the One-way ANOVA test was used to compare multiple samples. Then, pairwise comparisons were performed within the groups. P ≤ 0.05 was considered statistically significant.
[0051] 2 Results
[0052] 2.1 Establishment of cardiomyocyte aging model
[0053] D-galactose was used to induce cardiomyocyte senescence, and the cells were stained with a β-galactosidase kit. The cells with blue cytoplasm under the microscope were positively stained senescent cells. The experimental results showed that compared with the normal control group, the number of positively stained senescent cells in the D-galactose induced group cells reached more than 80% ( Figure 1 ).
[0054] 2.2 Changes of LDH and CK-MB in aging cardiomyocytes
[0055] The cell supernatants of each group were collected, and the concentrations of myocardial injury markers LDH and CK-MB in the Normoxia, H / R and HPostC groups were detected by ELISA. The results showed that compared with the Normoxia group, the levels of LDH and CK-MB in the H / R group were significantly increased; compared with the H / R group, the levels of LDH and CK-MB in the HPostC group were significantly decreased, indicating that hypoxic postconditioning can reduce the damage of aging myocardial cells ( Figure 2 ).
[0056] 2.3 Expression of LC3Ⅱ / Ⅰ, p62 and p-ULK1 in senescent cardiomyocytes
[0057] Western Blot was used to detect the ratio of LC3Ⅱ to LC3Ⅰ, the expression of p62, ULK1 and p-ULK1 in aged cardiomyocytes in the Normoxia, H / R and HPostC groups. The results showed that compared with the Normoxia group, the LC3Ⅱ / Ⅰ in the H / R group increased significantly, the expression level of p62 decreased significantly, the expression level of ULK1 remained basically unchanged, but the p-ULK1 / ULK1 increased significantly, indicating that the autophagy level of aged cardiomyocytes increased after hypoxia / reoxygenation treatment; compared with the H / R group, the LC3Ⅱ / Ⅰ in the HPostC group decreased significantly, the expression level of p62 increased significantly, the expression level of ULK1 remained basically unchanged, but the p-ULK1 / ULK1 decreased significantly, indicating that compared with hypoxia / reoxygenation, post-hypoxia treatment can reduce the autophagy level of aged cardiomyocytes ( Figure 3 ).
[0058] 2.4 Expression of piRNA-005854 in aging cardiomyocytes
[0059] In the early stage of the experiment, the aged cardiomyocytes of the Normoxia group, H / R group, and HPostC group were sequenced, and the sequencing results showed that piRNA-005854 (sequence: 5'-GTGCGCTATGCCGATCGGGTGTCCGCACTA-3', as shown in SEQ ID NO.1) was a differential gene among the three groups of cells. qRT-PCR was used to further verify the expression of piRNA-005854 in aged cardiomyocytes. The results showed that compared with the Normoxia group, the expression level of piRNA-005854 in the H / R group was significantly increased; compared with the H / R group, the expression level of piRNA-005854 in the HPostC group was significantly decreased, suggesting that piRNA-005854 may play an important role in the hypoxic post-processing of aged cardiomyocytes ( Figure 4 ).
[0060] 2.5 Validation of piRNA-005854 interference and overexpression in aging cardiomyocytes
[0061] In order to clarify the effect of piRNA-005854 on autophagy in aged cardiomyocytes of HPostC, piRNA-005854 interference (piRNA-005854inhibitor) and piRNA-005854 overexpression (piRNA-005854mimics) were transfected into aged cardiomyocytes, and the expression of piRNA-005854 was detected by qRT-PCR. The results showed that compared with the inhibitor-NC group, the expression of piRNA-005854 in the piRNA-005854inhibitor group was significantly reduced; while compared with the mimics-NC group, the expression of piRNA-005854 in the piRNA-005854mimics group was significantly increased; indicating that the piRNA-005854 interference and overexpression fragments were successfully transfected and could be stably expressed in aged cardiomyocytes ( Figure 5 ).
[0062] 2.6 Effect of piRNA-005854 on autophagy in aged cardiomyocytes
[0063] In order to further explore the effect of piRNA-005854 on autophagy in aged cardiomyocytes after HPostC, piRNA-005854inhibitor and inhibitor-NC were transfected into aged cardiomyocytes and then treated with HPostC. Then, Western blot was used to detect the protein expression of autophagy-related proteins LC3Ⅱ / Ⅰ and p62. The results showed that compared with the inhibitor-NC group, the level of LC3Ⅱ / Ⅰ in the piRNA-005854inhibitor group was significantly decreased, while the protein expression of p62 was significantly increased. At the same time, piRNA-005854mimics and mimics-NC were transfected into aged cardiomyocytes and then treated with HPostC. Western blot results showed that compared with the mimics-NC group, the level of LC3Ⅱ / Ⅰ in the piRNA-005854mimics group was significantly increased, while the protein expression level of p62 was decreased, indicating that aged cardiomyocytes treated with hypoxia regulated autophagy through piRNA-005854 ( Figure 6 ).
[0064] 2.7 Effect of piRNA-005854 on ULK1 phosphorylation in aged cardiomyocytes
[0065] To further explore the regulatory role of piRNA-005854 in autophagy, piRNA-005854inhibitor and piRNA-005854mimics were transfected into aged cardiomyocytes. After HPostC treatment, Western blot was used to detect the expression changes of ULK1 protein in aged cardiomyocytes. The results showed that compared with the inhibitor-NC group, the expression level of ULK1 total protein in the piRNA-005854inhibitor group did not change significantly, but the protein expression level of p-ULK1 was significantly decreased. Compared with the mimics-NC group, the expression level of ULK1 total protein in the piRNA-005854mimics transfection group also did not change significantly, but the protein expression level of p-ULK1 was significantly increased. This shows that piRNA-005854 regulates autophagy in aged cardiomyocytes after hypoxia treatment by regulating ULK1 phosphorylation ( Figure 7 ).
[0066] Although the preferred embodiments of the present invention have been described, those skilled in the art may make other changes and modifications to these embodiments once they have learned the basic creative concept. Therefore, the appended claims are intended to be interpreted as including the preferred embodiments and all changes and modifications that fall within the scope of the present invention.
[0067] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.
Claims
1. Use of a preparation for inhibiting piRNA-005854 in the preparation of a drug for treating cardiac ischemia-reperfusion injury, characterized in that: The nucleotide sequence of the piRNA-005854 is shown in SEQ ID NO.1, and the agent for inhibiting piRNA-005854 is the piRNA-005854 inhibitor shown in SEQ ID NO.
2.
2. The use according to claim 1, characterized in that: The drug inhibits apoptosis of senescent cardiomyocytes.
3. The use according to claim 2, characterized in that: The drug inhibits myocardial cell apoptosis caused by autophagy of senescent myocardial cells.
4. The use according to claim 3, characterized in that: The drug inhibits autophagy of senescent cardiomyocytes caused by increased LC3Ⅱ / Ⅰ and decreased p62.
5. The use according to claim 4, characterized in that: The drug inhibits the increase of LC3Ⅱ / Ⅰ and the decrease of p62 caused by the increase of ULK1 phosphorylation.
6. The use according to claim 5, characterized in that: The drug inhibits the increase in ULK1 phosphorylation induced by hypoxia-reoxygenation or hypoxic postconditioning.
Citation Information
Patent Citations
Screening method for lncRNA relevant to myocardial ischemia reperfusion and application
CN104404146A
PiRNA combination for detecting heart disease, and application thereof
CN106916885A
Application of piRNA-5938 and antisense nucleic acid thereof in diagnosis, prevention, treatment and prognosis evaluation of ischemic heart disease
CN107385033A
Oxygen-glucose deprivation reperfusion model of senescent SH-SY5Y cells as well as construction method and application of oxygen-glucose deprivation reperfusion model
CN115354027A
Method and kit for myocardial reperfusion, and method for attenuating or reducing myocardial reperfusion injury
US20190298664A1
